35 articles - From Friday Jul 15 2022 to Friday Jul 22 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| J Am Soc Nephrol |
Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes. Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes. |
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
Age and the Course of GFR in Persons Aged 70 and Above. The eGFR decline depended on sex and age and changed only marginally after multivariable adjustment but decelerated with increasing age. Equations including cystatin C demonstrated a nonlinear slope challenging the previously assumed linearity of the decline of eGFR in old age. |
Management of Intermittent Hemodialysis in the Critically Ill Patient. Intermittent hemodialysis will continue to be an important and commonly used KRT modality for AKI in patients with critical illness, especially in jurisdictions where resources are limited. There is an urgent need to harmonize the definition of hemodynamic instability related to KRT in clinical trials and robustly test strategies to combat it in this vulnerable patient population. |
| J Am Soc Nephrol |
Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria, proteinuria, and KFRT. Among patients with eGFR <30 mL/min per 1.73 m 2 , 44% were prescribed a rosuvastatin daily dose exceeding the FDA's recommended 10 mg daily dose. Our findings suggest the need for greater care in prescribing and monitoring rosuvastatin, particularly in patients who receive high doses, or who have severe CKD. |
Channel Function of Polycystin-2 in the Endoplasmic Reticulum Protects against Autosomal Dominant Polycystic Kidney Disease. Polycystin-2 in the ER appears to be critical for anticystogenesis and likely functions as a potassium ion channel to facilitate potassium-calcium counterion exchange for inositol trisphosphate-mediated calcium release. The results advance the understanding of ADPKD pathogenesis and provides proof of principle for pharmacotherapy by TRIC-B activators. |
Emerging Insights into Glomerular Vascular Pole and Microcirculation. A corollary is that the GFR is a net product of balance between the states of capillary perfusion, and that deviations from the balanced state would increase or decrease GFR. Taken together, these studies may pave the way to a more profound understanding of glomerular microcirculation under basal conditions and in progression of glomerulopathies. |
NMR Metabolomic Profiling and Urine Chemistries in Incident Kidney Stone Formers Compared to Controls. Although NMR-quantified metabolites did not improve discrimination, several urine metabolic profiles were identified that may improve understanding of kidney stone pathogenesis. |
Optimizing the Design and Analysis of Future AKI Trials. We also propose a road map and actionable recommendations to facilitate the adoption of the reviewed approaches. We hope that the resulting road map will help guide future clinical trial planning, maximize learning from AKI trials, and reduce the risk of missing important signals of benefit (or harm) from trial interventions. |
| Kidney Int |
A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Thus, anakinra was well tolerated and did not increase infections or cytopenias. The promising safety data and potential efficacy on CRP and IL-6 provide support for conducting definitive trials of IL-1 inhibition to improve outcomes in hemodialysis patients. |
Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease. Thus, our results demonstrated that disturbed lipid metabolism precedes the onset of CKD. These findings shed light on the mechanisms linking dyslipidemia to CKD and provide potential novel biomarkers for identifying individuals with early impaired kidney function at preclinical stages. |
TARGETING INFLAMMATORY MONOCYTES BY IMMUNE-MODIFYING NANOPARTICLES PREVENTS ACUTE KIDNEY ALLOGRAFT REJECTION. IMPs afforded significant protection from acute rejection, inhibiting both innate and adaptive alloimmunity. Thus, our current experimental findings, coupled with our earlier demonstration of IMP-induced protection in kidney ischemia-reperfusion injury, identify IMPs as a potential induction agent in kidney transplantation. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
| J Am Soc Nephrol |
| Kidney Int |
HIV at 40: Kidney Disease in HIV Treatment, Prevention, and Cure. Transplantation of kidney allografts from donors with HIV also offers a unique opportunity to study viral dynamics in the kidney, with implications for kidney health and for research towards HIV cure. In addition, HIV-transgenic animal models have provided important insights into kidney disease pathogenesis beyond HIV, and experience with HIV and HIV-related kidney disease has provided important lessons for future pandemics. |
Letters to the editors and authors’ replies
| J Am Soc Nephrol |
all remaining publications eg case reports, images of the month, etc…
| Clin J Am Soc Nephrol |
| J Am Soc Nephrol |
| Nephrol Dial Transplant |